

If you can't read this email, please [click here](#) to view online

**HEXACATH**  
PIONEER IN BIO ACTIVE COATING



## TITAN™ OPTiMAX™ THE NEW BENCHMARK IN ACS!

**TITAN™ OPTiMAX™ Bio-Active-Stent:  
demonstrated superiority vs. the best-in-class Drug-  
Eluting-Stent**

Co-primary superiority endpoint at 18 months of cardiac death,  
myocardial infarction & major bleeding

**3.7%**  
OPTiMAX™  
(n=989)


VS.

**7.8%**  
SYNERGY™  
(n=502)

(HR 2.17; 95% CI 1.36 - 3.45;  $p_{\text{superiority}} = 0.001$ )

## Reduced incidence of cardiac death and MI with OPTiMAX™ vs. SYNERGY™<sup>1</sup>

MACE event rates and Definite ST at 18 months<sup>1</sup>



As EFFECTIVE with a SUPERIOR SAFETY profile<sup>1</sup>

TIDES-ACS key results at 18 months:

OPTiMAX™ stent met the co-primary endpoint of superiority vs. SYNERGY™<sup>1</sup>

OPTiMAX™ demonstrated a reduced incidence of cardiac death, myocardial infarction, Definite ST vs. SYNERGY™ without significant difference in TLR<sup>1</sup>



## REMINDER... THE BASE-ACS TRIAL

**Ti TAN2™ 2<sup>nd</sup> generation Bio-Active-Stent demonstrated non-inferiority vs. 2<sup>nd</sup> generation Drug-Eluting-Stent**


**MACE at 60 months with Ti TAN2™ stent vs. Xience V® stent**



(HR 0.82; 95% confidence interval, 0.58-1.16; p=0.26 for superiority; p=<0.001 for non-inferiority)

[Access Full Results >](#)

**MACE event rates and  
Definite ST at 60 months**



### BASE-ACS key results at 60 months:

TITAN2™ stent met the primary endpoint of non-inferiority to Xience V®  
 TITAN2™ demonstrated a reduced incidence of cardiac death or myocardial infarction and, Definite ST with a significantly lower duration of DAPT (P<0.001) vs. Xience V®  
 The mean duration of clopidogrel use was 8.7 ± 3.6 versus 10.2 ± 3.0 months, respectively, (p<0.001).

OPTiMAX™ and TiTAN2™ are registered trademarks of Hexacath.  
 Xience V® is a registered trademark of the Abbott Group of Companies.  
 SYNERGY™ is registered trademarks of Boston Scientific and its affiliates.

1. EuroPCR 2018 - Late Breaking Trial.



You are receiving this email at [email address suppressed] because you attended one of the PCR family Courses, are a PCRonline member or are subscribed to EuroIntervention. You have an interest in cardiology topics.  
[Edit your subscription settings or unsubscribe.](#)

If you wish to unsubscribe from all our communications, please click here.

© 2018 Europa Group. All rights reserved.

Our offices:  
Europa Group  
19, allés Jean Jaurès BP 61508  
31015 Toulouse Cedex 6 France